Abstract:Background: The longitudinal monitoring of actionable oncogenes in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) is crucial for clinicians to evaluate current therapeutic response and adjust therapeutic strategies. Saliva-based electric field-induced release and measurement (EFIRM) is liquid biopsy platform to that can directly detect mutation genes with a small volume of samples. Herein, we compared the effectiveness of longitudinal monitoring for the combination of epidermal growth factor receptor (EGFR) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations between saliva-based EFIRM and plasma-based platforms (ddPCR and NGS) in two advanced NSCLC patients undergoing the treatment with osimertinib before and after local ablative therapy (LAT). Patients and Methods: Two patients with unresectable advanced NSCLC were enrolled into the National Institutes of Health Clinical Center (NIHCC) Study (ClinicalTrials.gov: 16-C-0092; local ablative therapy for the treatment of oligoprogressive, EGFR-mutated, non-small cell lung cancer after treatment with osimertinib). Serial collections of saliva, plasma, and metastatic tumor volume measurement by computed tomography (CT) were performed. Longitudinal paired saliva and plasma samples were analyzed for p.L858R EGFR, exon19 del EGFR, and p.E545K PIK3CA ctDNA using EFIRM (saliva) and ddPCR and NGS (plasma). Results: In Case 1, the saliva ctDNA curve of exon19 del EGFR by EFIRM demonstrated a strong similarity to those of tumor volume (R = 0.78, P = 0.00) and exon19 del EGFR in ddPCR (R = 0.53, P = 0.01). Moreover, the curve of p.E545K PIK3CA in EFIRM showed similarity to those of tumor volume (R = 0.70, P = 0.00) and p.E545K PIK3CA in NGS (R = 0.72, P = 0.00). In Case 2, the curve of p.E545K PIK3CA in EFIRM revealed a reverse relationship to that of tumor volume (R = -0.65, P = 0.01). Conclusion: In these two case reports, saliva-based EFIRM platform demonstrates a high level of concordance to plasma-based platforms (ddPCR and NGS) for longitudinally monitoring the combination of EGFR and PIK3CA ctDNA and can be a useful platform to monitor tumor progression and response to targeted therapy in NSCLC patients.

Technical Validation Of The Electric Field-Induced Release And Measurement (Efirm) Assay For The Detection Of Egfr Mutations In Circulating Cell Free Dna In Plasma And Saliva.

Electric Field-Induced Release and Measurement (EFIRM) <i>Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva</i>

P1.11-13 Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)

Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment.

EFIRM Liquid Biopsy (elb): Detection of Ultra-Short Circulating Tumor DNA (usctdna) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Evaluation of a Novel Saliva-Based Epidermal Growth Factor Receptor Mutation Detection for Lung Cancer: A Pilot Study.

Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer

Ultra-Short Circulating Tumor DNA (usctdna) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.

Clinical Validity of Electric Field Induced Release and Measurement (efirm) for Kras Mutation Detection in Circulating Dna Associated with Pancreatic Ductal Adenocarcinoma.

Single-Droplet Microsensor for Ultra-Short Circulating EFGR Mutation Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy

Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports

Multiplex Picoliter-Droplet Digital PCR for Quantitative Assessment of EGFR Mutations in Circulating Cell-Free DNA Derived from Advanced Non-Small Cell Lung Cancer Patients

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Assessment of EGFR Mutations in Plasma from Advanced NSCLC Patients by Modified Cell-Free DNA Extraction Method and Blocker PCR Assays

'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients

Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer

Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients